REHOVOT, Israel and BRIDGEWATER, N.J., July 26, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the three and six months ended June 30, 2017, and will host a corporate update conference call and webcast at 8:30am Eastern Time on Wednesday, August 9, 2017.
Conference Call & Webcast  
Wednesday, August 9, 2017 @ 8:30 am Eastern Time   
Toll Free: 877-780-3381
International: 913-312-1403
Conference ID: 2390109
Replays, Available through August 23rd: 
Toll-Free: 844-512-2921
International: 412-317-6671
Conference ID: 2390109

About Foamix Pharmaceuticals Ltd. Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Our clinical stage product candidates include our novel minocycline foam FMX101 for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

For more information, please visit
Contact:				Ilan Hadar, Country Manager & CFOFoamix Pharmaceuticals Ltd.		+972-8-9316233	US Investor RelationsMichael RiceLifeSci Advisors,

Primary Logo